Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors (SABR-PRIMeR)

NCT06937281 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT06937281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors (SABR-PRIMeR)
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
July 30, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastases